step 6 semaglutide clinical trial 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- controlled, phase 3 FLOWing with the SemagluTIDE — – Synthesis method of semaglutide -

Studies using dual-energy X-ray absorptiometry (DXA) demonstrate reductions in total fat mass up to 10.9 kg, with particular effectiveness in reducing visceral fatthe metabolically harmful abdominal fat strongly associated with cardiovascular and metabolic disease risk

Because once the dose is injected, you cant undo it

These properties include: the intranasal compound should have no unpleasant odor, should not be irritating to nasal mucosa or influence the sense of smell, and should be potent enough so that post-intranasal administration bioavailability of the drug can reach therapeutic efficacy

If you are taking any medication or supplement or have any medical conditions, consult your doctor before using this product